KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Short term Debt (2018 - 2025)

BioNTech SE's Short term Debt history spans 8 years, with the latest figure at $409.4 million for Q4 2025.

  • On a quarterly basis, Short term Debt fell 73.46% to $409.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $409.4 million, a 73.46% decrease, with the full-year FY2025 number at $397.4 million, down 74.24% from a year prior.
  • Short term Debt hit $409.4 million in Q4 2025 for BioNTech SE, down from $698.4 million in the prior quarter.
  • Over the last five years, Short term Debt for BNTX hit a ceiling of $11.1 billion in Q2 2022 and a floor of $37.3 million in Q3 2022.
  • Historically, Short term Debt has averaged $1.1 billion across 5 years, with a median of $428.1 million in 2023.
  • Biggest five-year swings in Short term Debt: soared 12451.18% in 2021 and later crashed 98.3% in 2023.
  • Tracing BNTX's Short term Debt over 5 years: stood at $1.4 billion in 2021, then plummeted by 41.18% to $801.0 million in 2022, then tumbled by 44.23% to $446.7 million in 2023, then skyrocketed by 245.27% to $1.5 billion in 2024, then plummeted by 73.46% to $409.4 million in 2025.
  • Business Quant data shows Short term Debt for BNTX at $409.4 million in Q4 2025, $698.4 million in Q3 2025, and $164.1 million in Q2 2025.